Formycon AG

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 11:37:08 2024-12-06 am EST			5-day change	1st Jan Change
52.00 ^EUR	+1.76%		+4.10%	-7.80%

Dec. 05	German Stocks Shrug Off Worsening Construction Slump	MT
Dec. 05	Formycon to Become Part of Germany's SDAX Index	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Formycon AG

German Stocks Shrug Off Worsening Construction Slump	Dec. 05	MT
Formycon to Become Part of Germany's SDAX Index	Dec. 05	MT
Auto1 and Evotec return to the MDax - No changes in the Dax	Dec. 05	RE
Formycon AG, Nine Months 2024 Earnings Call, Nov 28, 2024	Nov. 28
German Stocks Fall Ahead of Key Economic Data	Nov. 18	MT
Formycon Wins EU Panel's Backing for Eylea Biosimilar	Nov. 18	MT
Formycon AG Appoints Colin Bond as Director	Nov. 14	CI
Formycon Moves to Frankfurt Bourse's Prime Standard Market	Nov. 12	MT
Formycon Files Application to Transfer Listing to Frankfurt Bourse's Prime Standard Market	Nov. 04	MT
Fresenius Kabi and Formycon Receives U.S. FDA Approval for Biosimilar Otulfi (ustekinumab-aauz)	Sep. 30	CI
Global markets live: Stellantis, Apple, Spotify, Verizon, At&T...	Sep. 30
Formycon, Fresenius Unit Obtain US FDA Approval for Stelara Biosimilar Otulfi	Sep. 30	MT
Formycon Wins US Approval for Crohn's Disease Treatment Biosimilar	Sep. 29	MT
Formycon, Fresenius Gain EU Marketing Authorization for Stelara Biosimilar	Sep. 27	MT
Borse Frankfurt-News: Small caps: Recovery after setback	Aug. 16	DP
Formycon AG Reports Earnings Results for the Half Year Ended June 30, 2024	Aug. 13	CI
Formycon, Fresenius' Stelara Biosimilar for Inflammatory Diseases Secures EU Panel's Nod	Jul. 26	MT
US FDA Approves Formycon's Biosimilar to Treat Serious Retinal Diseases	Jul. 01	MT
Borse Frankfurt-News: Many winners and many losers (second-line stocks)	Jun. 18	DP
Formycon Starts Clinical Trials of Keytruda Biosimilar Candidate for Skin Cancer Therapy	Jun. 13	MT
Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25	CI
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	Mar. 18	MT
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative	Mar. 18	DJ
Formycon Wins Regulatory Nod for Lucentis Biosimilar in Saudi Arabia	Mar. 11	MT
Formycon Sells 9% Interest to Gedeon Richter for EUR83 Million	Jan. 30	MT

Formycon AG is a Germany-based company engaged in providing biosimilar drugs and formulations. Its business activities are focused on the development and marketing of biopharmaceuticals that are similar to existing drugs, for which the patent protection is expiring. The Company focuses on treatments in the area of ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval. Its biosimilar product pipeline consists of four candidates in pre-clinical and clinical testing phases, including FYB201, a biosimilar candidate for Lucentis; FYB202, a biosimilar candidate for Stelara; FYB203, a biosimilar candidate for Eylea, and FYB205.

Employees

239

Sector

Biotechnology & Medical Research

Calendar

2024-12-11 - MWB Research Roundtable Conference

More about the company